{"id":479429,"date":"2021-04-21T08:03:12","date_gmt":"2021-04-21T12:03:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/"},"modified":"2021-04-21T08:03:12","modified_gmt":"2021-04-21T12:03:12","slug":"mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/","title":{"rendered":"Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WORCESTER, Mass., April  21, 2021  (GLOBE NEWSWIRE) &#8212; Mustang Bio, Inc. (\u201cMustang\u201d) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, and Knut Niss, Ph.D., Chief Technology Officer, will participate in Chardan\u2019s 5<sup>th<\/sup> Annual Genetic Medicines Manufacturing Summit, taking place virtually on April 26 and 27, 2021. The company will participate in a fireside chat on Monday, April 26, 2021, at 3:15 p.m. ET and will also participate in one-on-one meetings during the conference. A webcast of the company\u2019s fireside chat will be available on the Events page of the Investor Relations section of Mustang\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lm37_pBokrzmTNrpb3FFPxaUYDCWwUm1L9L9hBwu_eREVQKTxiYKCSaP9jQcAHo1nGhilLvyTdCh1URTUJJrJmDqcr_kbY7wsrGv9lYwyZI=\" rel=\"nofollow noopener\" target=\"_blank\">www.mustangbio.com<\/a>, for approximately 30 days after the meeting.<\/p>\n<p align=\"justify\">\n        <strong>About Mustang Bio<\/strong><br \/>\n        <br \/>Mustang Bio, Inc. (\u201cMustang\u201d) is a clinical-stage biopharmaceutical company focused on translating today\u2019s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (\u201cSEC\u201d). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lm37_pBokrzmTNrpb3FFP1AoA9azduQJZycNyBvM_GW59q1-062u7BeZxl14CfDz5wq6emxuwbn9O-t2GgSTMQHCi1Rbvhy8TpMOf9nOy4E=\" rel=\"nofollow noopener\" target=\"_blank\">www.mustangbio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward\u2010Looking Statements<br \/><\/strong>This press release may contain \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management\u2019s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.<\/p>\n<p>\n        <strong>Company Contacts:<\/strong><br \/>\n        <br \/>Jaclyn Jaffe and Bill Begien<br \/>Mustang Bio, Inc.<br \/>(781) 652-4500<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XamPC2PA1Kdrpnm_QnwQHxX4HT4UuncyPG9jEAnMt_1kbzu6aln_FjA-0SDit3lNTJggQptq0s7A50MyhLxkhw==\" rel=\"nofollow noopener\" target=\"_blank\">ir@mustangbio.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Daniel Ferry<br \/>LifeSci Advisors, LLC<br \/>(617) 430-7576<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Aw44bkniBqF9JPvPVS4DhW9QqSJDGz5LSbUfEembtXayBOoq3wTRr6rESH3i6Cu1JgcGw2rK7uTB7CnwaxA75a0xh2j3JcHBaDK2Q_qlcYDcuLWr-a9XaOldKbsX1dM_\" rel=\"nofollow noopener\" target=\"_blank\">daniel@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Relations Contact:<\/strong><br \/>\n        <br \/>Tony Plohoros<br \/>6 Degrees<br \/>(908) 591-2839<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kp3f_XutyKkua0QcetVxN5HRKVNfH5zSc4MAgGojWbgCqG40b6BM6Q5mimq0QO1RNnH7fy9T9WUMsWSTts7QQdCNeiT9dQtsHymhvnhsZQU=\" rel=\"nofollow noopener\" target=\"_blank\">tplohoros@6degreespr.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDU1OCM0MTMwODM1IzIwNDk3NTc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e6bce8b1-0f68-4815-b439-21049a49626a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WORCESTER, Mass., April 21, 2021 (GLOBE NEWSWIRE) &#8212; Mustang Bio, Inc. (\u201cMustang\u201d) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, and Knut Niss, Ph.D., Chief Technology Officer, will participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit, taking place virtually on April 26 and 27, 2021. The company will participate in a fireside chat on Monday, April 26, 2021, at 3:15 p.m. ET and will also participate in one-on-one meetings during the conference. A webcast of the company\u2019s fireside chat will be available on the Events page of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-479429","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WORCESTER, Mass., April 21, 2021 (GLOBE NEWSWIRE) &#8212; Mustang Bio, Inc. (\u201cMustang\u201d) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, and Knut Niss, Ph.D., Chief Technology Officer, will participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit, taking place virtually on April 26 and 27, 2021. The company will participate in a fireside chat on Monday, April 26, 2021, at 3:15 p.m. ET and will also participate in one-on-one meetings during the conference. A webcast of the company\u2019s fireside chat will be available on the Events page of &hellip; Continue reading &quot;Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-21T12:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDU1OCM0MTMwODM1IzIwNDk3NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit\",\"datePublished\":\"2021-04-21T12:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/\"},\"wordCount\":580,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDU1OCM0MTMwODM1IzIwNDk3NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/\",\"name\":\"Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDU1OCM0MTMwODM1IzIwNDk3NTc=\",\"datePublished\":\"2021-04-21T12:03:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDU1OCM0MTMwODM1IzIwNDk3NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyMDU1OCM0MTMwODM1IzIwNDk3NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/","og_locale":"en_US","og_type":"article","og_title":"Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk","og_description":"WORCESTER, Mass., April 21, 2021 (GLOBE NEWSWIRE) &#8212; Mustang Bio, Inc. (\u201cMustang\u201d) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, and Knut Niss, Ph.D., Chief Technology Officer, will participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit, taking place virtually on April 26 and 27, 2021. The company will participate in a fireside chat on Monday, April 26, 2021, at 3:15 p.m. ET and will also participate in one-on-one meetings during the conference. A webcast of the company\u2019s fireside chat will be available on the Events page of &hellip; Continue reading \"Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-21T12:03:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDU1OCM0MTMwODM1IzIwNDk3NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit","datePublished":"2021-04-21T12:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/"},"wordCount":580,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDU1OCM0MTMwODM1IzIwNDk3NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/","name":"Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDU1OCM0MTMwODM1IzIwNDk3NTc=","datePublished":"2021-04-21T12:03:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDU1OCM0MTMwODM1IzIwNDk3NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDU1OCM0MTMwODM1IzIwNDk3NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mustang-bio-to-participate-in-chardans-5th-annual-genetic-medicines-manufacturing-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mustang Bio to Participate in Chardan\u2019s 5th Annual Genetic Medicines Manufacturing Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=479429"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479429\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=479429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=479429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=479429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}